• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Diabetes: FDA clears DexCom’s mobile apps

Diabetes: FDA clears DexCom’s mobile apps

January 26, 2015 By Brad Perriello

Diabetes: FDA clears DexCom's mobile app

Dexcom Inc. (NSDQ:DXCM) won de novo approval from the FDA for the 1st U.S. app to wirelessly connect a patient’s blood glucose monitor with up to 5 mobile devices.

Although patients have created open-source versions to accomplish the same thing, the FDA said DexCom’s Share Direct Secondary Displays system is the 1st legally marketed solution. The news sent DXCM shares up more than 5% this morning.

"This innovative technology has been eagerly awaited by the diabetes community, especially caregivers of children with diabetes who want to monitor their glucose levels remotely," Alberto Gutierrez, director of the FDA’s Office of In Vitro Diagnostics & Radiological Health, said in prepared remarks.

The federal watchdog agency cleared the device using its de novo pathway for novel, low- to moderate-risk medical devices, designating the Share system as a Class II device that’s exempt from the FDA’s most stringent pre-market approval clinical trial requirements. That clears the way for other medtech makers to put similar systems on the market without needing a PMA.

"Exempting devices from pre-market review is part of the FDA’s effort to ensure these products provide accurate and reliable results while still encouraging the development of devices that meet the needs of people living with diabetes and their caregivers," Gutierrez said.

DexCom said the Share system is designed to display data from the G4 Platinum device using 2 apps, 1 on the patient’s mobile device and the 2nd on another person’s mobile device. The patient can designate "followers" to receive real-time CGM data. The apps work with Apple‘s (NSDQ:AAPL) iPhone or iPod Touch device, the San Diego-based company said, adding that it plans to make the technology available for Google‘s (NSDQ:GOOG) Android-based devices "in the future." The Share receiver is expected to ship in early March, according to a press release.

"The Dexcom Share receiver represents a significant step forward for our company and our mobile strategy, but more importantly, it will provide a huge improvement for people managing their diabetes and for those parents and caregivers who help them each and every day," DexCom president & CEO Kevin Sayer said in a statement. "The FDA understands the importance of this type of innovation and the need to regulate it appropriately, and we could not be more pleased with the speed at which they reviewed and approved this important innovation."

DXCM shares were trading at $60.84 apiece today in late-morning activity, up 5.0%.

Filed Under: Diabetes, Digital Health, Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Alphabet (Google), Apple, De Novo Clearance, Dexcom

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy